Shuttle Pharmaceuticals Holdings, Inc.
SHPHHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeShuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. With a market capitalization of $2.1M, it sits in micro-cap territory. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development.
Market Cap
$2.1M
Beta
1.22
P/E (TTM)
35.40
P/E (Fwd)
—
EPS (TTM)
$0.10
EPS (Fwd)
—
ROE
-326.4%
ROA
-81.7%
Cash
$1.1M
Total Debt
$214,013
Free CF
$740,942
52W Change
-89.9%
Annual Financials
Cash vs Debt
Where SHPH stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, SHPH finished 50.07% below its 150-day moving average ($6.99) and 64.09% below its 200-day moving average ($9.72). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SHPH overbought or oversold?
At the September 3, 2026 close, SHPH's RSI(14) was 29.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Shuttle Pharmaceuticals Holdings, Inc. holds $1.1M in cash against $214K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $741K in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -326.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, SHPH has financial flexibility that may help navigate uncertain periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing SHPH.